Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers ML, Armstrong SA, Brown P, De Carvalho D, Jabado N, Marshall L, Rivera M, Smith M, Adamson PC, Barone A, Baumann C, Blackman S, Buenger V, Donoghue M, Duncan AD, Fox E, Gadbaw B, Hattersley M, Ho P, Jacobs I, Kelly MJ, Kieran M, Lesa G, Ligas F, Ludwinski D, McDonough J, Nikolova Z, Norga K, Senderowicz A, Taube T, Weiner S, Karres D, Vassal G. Pearson AD, et al. Among authors: stegmaier k. Eur J Cancer. 2020 Nov;139:135-148. doi: 10.1016/j.ejca.2020.08.014. Epub 2020 Sep 26. Eur J Cancer. 2020. PMID: 32992153 Review.
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia.
Larrue C, Mouche S, Lin S, Simonetta F, Scheidegger NK, Poulain L, Birsen R, Sarry JE, Stegmaier K, Tamburini J. Larrue C, et al. Among authors: stegmaier k. Leukemia. 2023 Apr;37(4):765-775. doi: 10.1038/s41375-023-01835-x. Epub 2023 Feb 4. Leukemia. 2023. PMID: 36739349 Free PMC article.
Depletion of creatine phosphagen energetics with a covalent creatine kinase inhibitor.
Darabedian N, Ji W, Fan M, Lin S, Seo HS, Vinogradova EV, Yaron TM, Mills EL, Xiao H, Senkane K, Huntsman EM, Johnson JL, Che J, Cantley LC, Cravatt BF, Dhe-Paganon S, Stegmaier K, Zhang T, Gray NS, Chouchani ET. Darabedian N, et al. Among authors: stegmaier k. Nat Chem Biol. 2023 Jul;19(7):815-824. doi: 10.1038/s41589-023-01273-x. Epub 2023 Feb 23. Nat Chem Biol. 2023. PMID: 36823351 Free PMC article.
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
Pearson AD, DuBois SG, Buenger V, Kieran M, Stegmaier K, Bandopadhayay P, Bennett K, Bourdeaut F, Brown PA, Chesler L, Clymer J, Fox E, French CA, Germovsek E, Giles FJ, Bender JG, Hattersley MM, Ludwinski D, Luptakova K, Maris J, McDonough J, Nikolova Z, Smith M, Tsiatis AC, Vibhakar R, Weiner S, Yi JS, Zheng F, Vassal G. Pearson AD, et al. Among authors: stegmaier k. Eur J Cancer. 2021 Mar;146:115-124. doi: 10.1016/j.ejca.2021.01.018. Epub 2021 Feb 16. Eur J Cancer. 2021. PMID: 33601323 Free article. Review.
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia.
Aubrey BJ, Cutler JA, Bourgeois W, Donovan KA, Gu S, Hatton C, Perlee S, Perner F, Rahnamoun H, Theall ACP, Henrich JA, Zhu Q, Nowak RP, Kim YJ, Parvin S, Cremer A, Olsen SN, Eleuteri NA, Pikman Y, McGeehan GM, Stegmaier K, Letai A, Fischer ES, Liu XS, Armstrong SA. Aubrey BJ, et al. Among authors: stegmaier k. Nat Cancer. 2022 May;3(5):595-613. doi: 10.1038/s43018-022-00366-1. Epub 2022 May 9. Nat Cancer. 2022. PMID: 35534777 Free PMC article.
Pharmacological targeting of the cancer epigenome.
Mabe NW, Perry JA, Malone CF, Stegmaier K. Mabe NW, et al. Among authors: stegmaier k. Nat Cancer. 2024 Jun;5(6):844-865. doi: 10.1038/s43018-024-00777-2. Epub 2024 Jun 27. Nat Cancer. 2024. PMID: 38937652 Review.
Proteomic and genetic approaches identify Syk as an AML target.
Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K. Hahn CK, et al. Among authors: stegmaier k. Cancer Cell. 2009 Oct 6;16(4):281-94. doi: 10.1016/j.ccr.2009.08.018. Cancer Cell. 2009. PMID: 19800574 Free PMC article.
162 results